Cargando…

Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China

Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we establish...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Haisu, Wang, Qian, Deng, Jiankai, Li, Hengchun, Zhang, Yingkun, Chen, Zhilong, Ji, Tianxin, Liu, Wenming, Zheng, Xuehua, Ma, Qinghua, Sun, Xinxin, Zhang, Yudi, Yu, Xuegao, He, Mengzhang, Chen, Ling, Feng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583180/
https://www.ncbi.nlm.nih.gov/pubmed/35764207
http://dx.doi.org/10.1016/j.virs.2022.06.006
_version_ 1784813013539225600
author Yi, Haisu
Wang, Qian
Deng, Jiankai
Li, Hengchun
Zhang, Yingkun
Chen, Zhilong
Ji, Tianxin
Liu, Wenming
Zheng, Xuehua
Ma, Qinghua
Sun, Xinxin
Zhang, Yudi
Yu, Xuegao
He, Mengzhang
Chen, Ling
Feng, Ying
author_facet Yi, Haisu
Wang, Qian
Deng, Jiankai
Li, Hengchun
Zhang, Yingkun
Chen, Zhilong
Ji, Tianxin
Liu, Wenming
Zheng, Xuehua
Ma, Qinghua
Sun, Xinxin
Zhang, Yudi
Yu, Xuegao
He, Mengzhang
Chen, Ling
Feng, Ying
author_sort Yi, Haisu
collection PubMed
description Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201–1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72–200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China.
format Online
Article
Text
id pubmed-9583180
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wuhan Institute of Virology, Chinese Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-95831802022-10-20 Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China Yi, Haisu Wang, Qian Deng, Jiankai Li, Hengchun Zhang, Yingkun Chen, Zhilong Ji, Tianxin Liu, Wenming Zheng, Xuehua Ma, Qinghua Sun, Xinxin Zhang, Yudi Yu, Xuegao He, Mengzhang Chen, Ling Feng, Ying Virol Sin Research Article Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201–1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72–200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China. Wuhan Institute of Virology, Chinese Academy of Sciences 2022-06-25 /pmc/articles/PMC9583180/ /pubmed/35764207 http://dx.doi.org/10.1016/j.virs.2022.06.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Yi, Haisu
Wang, Qian
Deng, Jiankai
Li, Hengchun
Zhang, Yingkun
Chen, Zhilong
Ji, Tianxin
Liu, Wenming
Zheng, Xuehua
Ma, Qinghua
Sun, Xinxin
Zhang, Yudi
Yu, Xuegao
He, Mengzhang
Chen, Ling
Feng, Ying
Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China
title Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China
title_full Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China
title_fullStr Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China
title_full_unstemmed Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China
title_short Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China
title_sort seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from guangdong and shandong provinces, china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583180/
https://www.ncbi.nlm.nih.gov/pubmed/35764207
http://dx.doi.org/10.1016/j.virs.2022.06.006
work_keys_str_mv AT yihaisu seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT wangqian seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT dengjiankai seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT lihengchun seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT zhangyingkun seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT chenzhilong seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT jitianxin seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT liuwenming seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT zhengxuehua seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT maqinghua seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT sunxinxin seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT zhangyudi seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT yuxuegao seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT hemengzhang seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT chenling seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina
AT fengying seroprevalenceofneutralizingantibodiesagainstadenovirustype26and35inhealthypopulationsfromguangdongandshandongprovinceschina